Nerivio is an FDA-cleared, drug-free therapy for the acute and preventive treatment of migraine, with or without aura. It is available for patients ages 8 and up in the U.S. and for those 12 and up in other locations where Nerivio is offered.

Nerivio should not be used by people with uncontrolled epilepsy, an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device. Such use could cause electric shock, electrical interference or serious injuries or medical conditions.

Nerivio has not been evaluated in people with congestive heart failure (CHF), severe cardiac or cerebrovascular disease, for pregnancy, or those under the age of 8. Nerivio should only be applied on the upper arm over dry, healthy skin with normal physical sensation and without any metallic implants or in proximity to cancerous lesions. For full user instructions and safety information, please see the Nerivio User Manual.

Use in patients under the age of 8 has not been evaluated. Speak to your pediatrician, who is the most familiar with your adolescent’s medical history.

A clinical study of women who were pregnant and used Nerivio for their migraine during their pregnancy through three months postpartum found Nerivio to be safe and did not increase the risk of adverse pregnancy outcomes. Thus, Nerivio may offer a non-pharmacological treatment for women with migraine during pregnancy and in the months following delivery.